ENvue Medical, Inc. FEED
- Market cap
- $950.0K
- P/E
- 0.0×
Follow FEED
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87,120.00 | 97,152.00 | 74,184.00 | 51,744.00 | 14,124.00 | 17,952.00 | 5,808.00 | 957.00 | 600.60 | 25.08 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 224,400.00 | 193,248.00 | 132,000.00 | 118,800.00 | 92,400.00 | 110,616.00 | 35,904.00 | 10,032.00 | 2,006.40 | 1,950.00 |
High Price
|
|||
| 10 | 12 | 10 | 14 | 12 | 16 | 14 | 16 | 31 | 14 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 0 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 3 |
Revenue
|
|||
| 61.57% | 63.18% | 50.31% | 53.02% | 34.35% | 45.43% | 22.21% | 67.32% | 58.95% | 5.99% |
Gross Margin
|
|||
| (3) | (5) | (4) | (6) | (4) | (14) | (5) | (4) | (4) | (18) |
EBT
|
|||
| (1,185.15%) | (2,061.51%) | (1,346.23%) | (1,096.42%) | (691.97%) | (840.71%) | (719.81%) | (161.28%) | (144.10%) | (724.32%) |
EBT Margin
|
|||
| (3) | (5) | (4) | (6) | (4) | (14) | (5) | (4) | (4) | (18) |
Net Income
|
|||
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
Depreciation
|
|||
| 1,145.00 | 1,195.00 | 1,590.00 | 1,766.67 | 1,557.50 | 1,695.00 | 683.64 | 1,756.15 | 1,162.73 | 48.81 |
Revenue/Sh
|
|||
| (16,376.18) | (30,903.46) | (16,904.45) | (21,922.95) | (10,677.07) | (15,048.94) | (5,071.33) | (2,799.80) | (1,648.26) | (320.41) |
Earnings/Sh
|
|||
| (7,665.00) | (10,910.00) | (17,750.00) | (12,913.33) | (8,477.50) | (4,367.00) | (6,395.45) | (2,770.77) | (1,143.64) | (179.20) |
Cash Flow/Sh
|
|||
| (40.00) | 0.00 | (40.00) | 0.00 | (5.00) | (3.00) | (2.73) | (0.77) | (1.36) | (1.15) |
Capex/Sh
|
|||
| (7,705.00) | (10,910.00) | (17,790.00) | (12,913.33) | (8,482.50) | (4,370.00) | (6,398.18) | (2,771.54) | (1,145.00) | (180.34) |
Free CF/Sh
|
|||
| (12,495.00) | 18,170.00 | 2,315.00 | 4,493.33 | 5,985.00 | 6,313.00 | 2,939.09 | 3,067.69 | 285.00 | 640.48 |
Book Value/Sh
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 138.34 | 99.86 | 60.12 | 42.59 | 12.95 | 16.20 | 8.88 | 0.86 | 0.67 | 0.57 |
PS Ratio
|
|||
| 0.00 | 6.57 | 41.47 | 16.79 | 3.37 | 4.35 | 2.07 | 0.49 | 2.73 | 0.04 |
PB Ratio
|
|||
| 144.43 | 93.72 | 66.41 | 43.06 | 0.91 | 11.67 | 5.32 | (0.56) | 0.39 | (0.67) |
EV/Sales
|
|||
| (21.46) | (10.26) | (5.93) | (5.88) | (0.17) | (4.53) | (0.57) | 0.36 | (0.39) | 0.18 |
EV/FCF
|
|||
| (2) | (2) | (4) | (4) | (3) | (4) | (7) | (4) | (3) | (9) |
Op' Cash Flow
|
|||
| 0 | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| (2) | (2) | (4) | (4) | (3) | (4) | (7) | (4) | (3) | (9) |
FCF
|
|||
| 0 | 4 | 1 | 1 | 5 | 6 | 3 | 4 | 1 | 1 |
Working Cap'
|
|||
| — | — | — | — | 0 | 0 | 0 | — | — | 1 |
Total Debt
|
|||
| 0 | (4) | (1) | (1) | (8) | (8) | (3) | (3) | (1) | (3) |
Net Debt
|
|||
| (2) | 4 | 0 | 1 | 2 | 6 | 3 | 4 | 1 | 33 |
Sh' Equity
|
|||
| (573.08%) | (119.34%) | (262.91%) | (284.58%) | (52.57%) | (165.65%) | (92.67%) | (59.13%) | (71.92%) | (74.97%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | (32,193.75%) | 0.00% | 0.00% | (602.40%) | (304.61%) | 0.00% | (47.18%) |
ROIC
|
|||
| 113.19% | (159.86%) | (901.08%) | (430.46%) | (180.78%) | (226.23%) | (168.51%) | (102.78%) | (160.56%) | (98.32%) |
ROE
|
|||
ENvue Medical, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SSKN Strata Skin Sciences, Inc. | $1.0M | 0.0× | Compare |
| THMO ThermoGenesis Holdings, Inc. | $1.1M | 0.0× | Compare |
| DYNTQ Dynatronics Corporation | $1.2M | 0.0× | Compare |
| DHAI DIH Holding US, Inc. | $1.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PFSA PROFUSA, Inc. | $1.6M | 0.0× | Compare |
| AFIB Acutus Medical, Inc. | $1.7M | 0.0× | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | 0.0× | Compare |
| MOTS Motus GI Holdings, Inc. | $420.0K | 0.0× | Compare |
ENvue Medical, Inc. (FEED) key facts
- ENvue Medical, Inc. (FEED) is a Medical Devices company in the Healthcare sector.
- ENvue Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 million, roughly unchanged from fiscal 2024.
- As of September 25, 2026, FEED traded at $0.41, a market capitalization of $950,000.00.
- Return on equity was −98.3% and debt-to-equity 0.04.
ENvue Medical, Inc. (FEED) Latest News
15 Sep
ENvue Medical, Inc. (FEED) issued an update on its Nasdaq listing status. Nasdaq listing compliance directly determines continued public trading access and can sharply move investor sentiment and share price.
9 Sep
ENvue Medical resumes U.S. commercial shipments of NanoVibronix PainShield and begins fulfilling open distributor orders. Resumption of shipments and order fulfillment supports revenue recovery without indicating major strategic shifts.
2 Sep
ENvue Medical has been selected to exhibit its ENvue Navigation Platform at the Vizient Innovative Technology Exchange. Exhibition at major technology exchange provides visibility for ENvue platform that may support adoption and partnerships.
18 Aug
ENvue Medical, Inc. (FEED) enters exclusive UroShield® distribution agreement carrying minimum purchase commitments of approximately $2.6 million. Secured $2.6 million minimum purchase commitments expand revenue visibility and distribution reach for core product.
12 Aug
ENvue Medical, Inc. (FEED) secures equity financing facility of up to $50 million to support commercial growth, technology expansion and strategic acquisitions. Up to $50 million equity facility directly funds major growth initiatives and acquisitions that can materially shift company trajectory.
4 Aug
ENvue Medical, Inc. (FEED) is relocating NanoVibronix manufacturing to the United States and consolidating R&D in Tel Aviv, Israel, to improve operational efficiencies and reduce costs. Manufacturing relocation and R&D consolidation directly improve cost structure and efficiency, materially affecting financial performance and operations.
9 Jul
ENvue Medical unveils its first robotic-assisted artificial intelligence feeding tube automation tool. Launch of first robotic AI feeding tube tool positions company for major gains in medical automation market.
9 Jun
ENvue Medical launches AI Training Platform establishing artificial intelligence foundation for robotic feeding tube navigation. AI platform launch advances core robotic navigation technology with potential to alter competitive positioning.
3 Jun
ENvue Medical published an independent study showing its ENvue Navigation Platform delivers major safety, time, and cost benefits across a multi-hospital system. Positive independent study results on platform performance may support wider adoption and modestly improve market perception.
13 May
ENvue Medical announces health system renewal extending platform adoption through 2028. Health system renewal locks in platform adoption and revenue through 2028, significantly boosting long-term stability and investor confidence.
12 May
ENvue Medical (FEED) secures three-year contract renewal with 12-hospital U.S. health network, establishing ENvue™ Navigation Platform as standard of care. Three-year renewal with 12-hospital network validates ENvue platform as standard of care, ensuring revenue growth and strengthening market position.
8 May
ENvue Medical, Inc. (FEED) secures USPTO Notice of Allowance for patent on ultrasound-enhanced cannabinoid drug delivery technology, expanding its intellectual property portfolio. USPTO patent allowance for ultrasound-enhanced cannabinoid delivery strengthens IP portfolio and supports moderate product innovation potential.
7 May
ENvue Medical, Inc. (FEED) secures three-year renewal of purchasing agreement with Group Purchasing Organization (GPO) for one of the largest U.S. health systems operating over 90 hospitals. Three-year renewal with GPO for major health system over 90 hospitals locks in substantial recurring revenue and strengthens market position.
20 Apr
ENvue Medical, Inc. (FEED) announces its 40th U.S. hospital customer: a Virginia medical center affiliated with the Mayo Clinic Care Network. Securing the 40th U.S. hospital customer, including a Mayo Clinic affiliate, demonstrates accelerating adoption and strengthens market positioning.
16 Apr
ENvue Medical, Inc. (FEED) issued a stockholder letter and provided a corporate update. Stockholder letter and corporate update address strategic progress and operations, moderately influencing financial performance and investor sentiment.
24 Mar
ENvue Medical expands presence within a major Michigan health system, growing U.S. hospital footprint to 39. Expansion into a major health system and increase to 39 U.S. hospitals marks significant market penetration and growth.
24 Feb
ENvue Medical, Inc. (FEED) received a USPTO Notice of Allowance for a patent on a feeding tube integrating electromagnetic navigation and direct visualization via an internal camera, strengthening its patent portfolio. USPTO Notice of Allowance for innovative feeding tube technology enhances ENvue Medical's IP protection and competitive positioning in medical devices.
14 Feb
ENvue Medical, Inc. (FEED) has seen an increase in insider holdings over the past year, indicating confidence from company executives in its future performance. This move may reflect positive expectations regarding the company's growth and market position. Insider buying typically signals confidence in the company's future, which may moderately influence market sentiment and performance.
4 Feb
ENvue Medical, Inc. (FEED) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect broader market trends or specific developments related to the company, potentially influencing its stock performance and investor sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
31 Jan
ENvue Medical, Inc. (FEED) was featured in a broadcast by New to The Street on Bloomberg, reaching audiences across the U.S., MENA, and Latin America. The segment highlighted the company's innovative medical solutions and its commitment to improving patient care. This exposure is expected to enhance brand visibility and attract potential investors and partners in the healthcare sector. Increased visibility through media exposure may moderately influence investor sentiment and market positioning.
28 Jan
ENvue Medical, Inc. has entered into a strategic partnership with U-Deliver to distribute its over-the-counter reusable ENFit syringe line in the U.S. market. This collaboration aims to enhance the availability of ENvue's innovative syringe products, which are designed for safe and effective medication delivery. The partnership is expected to leverage U-Deliver's distribution capabilities to reach a broader customer base, thereby increasing market penetration and sales potential for ENvue Medical. The partnership with U-Deliver is a significant strategic move that could enhance market reach and sales for ENvue Medical.
23 Jan
New to The Street has expanded its global broadcast footprint, now reaching audiences across the U.S., Middle East, and North Africa. This expansion aims to enhance visibility for companies like ENvue Medical, Inc. (FEED) by providing a broader platform for their innovations and developments. The initiative is expected to facilitate greater engagement with investors and stakeholders in these regions. The expansion of broadcast reach may moderately influence ENvue Medical's visibility and investor engagement, but its overall impact on the company's trajectory is expected to be limited.
21 Jan
ENvue Medical, Inc. has appointed Marc Waldman as Vice President of Commercial. Waldman brings extensive experience in the medical device industry, having held leadership roles at several prominent companies. His appointment is expected to enhance ENvue's commercial strategy and drive growth in the market. The appointment of an experienced executive may positively influence the company's commercial strategy and market positioning.
14 Jan
ENvue Medical, Inc. has launched over-the-counter reusable ENFit syringes aimed at enhancing feeding and medication delivery without the need for a prescription. This product is designed to improve accessibility for patients requiring enteral feeding and medication administration, aligning with the company's commitment to innovative healthcare solutions. The launch of over-the-counter reusable ENFit syringes is a significant strategic move that could enhance market presence and investor sentiment.
10 Jan
ENvue Medical, Inc. (FEED) has announced the launch of a new development and integration program aimed at enhancing its product offerings and operational capabilities. This initiative is expected to streamline processes and improve the overall efficiency of the company's services, positioning ENvue Medical for future growth in the healthcare sector. The launch of a new development and integration program is likely to significantly impact the company's operational capabilities and market positioning.
9 Jan
ENvue Medical, Inc. has launched a new program aimed at alleviating patient pain and discomfort associated with indwelling nasogastric tubes. This initiative is based on previously published, peer-reviewed clinical research, highlighting the company's commitment to improving patient care and addressing significant healthcare challenges. The launch of a program addressing patient discomfort with nasogastric tubes represents a significant strategic move that could enhance ENvue Medical's market position and investor sentiment.
8 Jan
ENvue Medical, Inc. (FEED) is scheduled to ring the Nasdaq Opening Bell on Wednesday, January 14th, 2026. This event marks a significant moment for the company as it highlights its presence in the public market and may enhance its visibility among investors and stakeholders. Ringing the Nasdaq Opening Bell is a notable event that can positively influence market sentiment and visibility but is unlikely to have a profound impact on the company's long-term trajectory.
18 Dec
ENvue Medical, Inc. (formerly NanoVibronix) has secured reimbursement for its UroShield® Kit in the UK. This development is expected to enhance the product's accessibility and adoption within the healthcare system, potentially leading to increased sales and market presence for the company. Securing reimbursement in the UK is a significant strategic move that could enhance market penetration and financial performance.
ENvue Medical, Inc. has secured reimbursement for its UroShield® Kit in the UK, marking a significant milestone for the company. This reimbursement approval is expected to enhance the product's market accessibility and potentially increase sales, as it allows healthcare providers to receive compensation for its use. The UroShield® Kit is designed to prevent catheter-associated urinary tract infections, addressing a critical need in patient care. Securing reimbursement in the UK is a significant strategic move that could enhance market penetration and sales growth for the UroShield® Kit.
15 Dec
ENvue Medical has appointed David Johnson, a seasoned executive in the healthcare industry, as its new Chairman. Johnson brings extensive experience and leadership skills to the role, which is expected to enhance the company's strategic direction and operational effectiveness. His appointment is seen as a positive move for ENvue Medical as it seeks to strengthen its position in the healthcare market. The appointment of a veteran executive may moderately influence the company's strategic direction and operational performance.